The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation

Amanda J. Abraham; Hannah K. Knudsen; Tanja C. Rothrauff; Paul M. Roman

doi:10.1016/j.jsat.2010.01.003

The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation

Amanda J. Abraham, Hannah K. Knudsen, Tanja C. Rothrauff, Paul M. Roman

Behavioral Science

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Organizational participation in clinical research may lead to adoption of the intervention by treatment agencies, but it is not known whether research involvement enhances innovativeness beyond the specific interventions that are tested. The National Institute on Drug Abuse's Clinical Trials Network (CTN) is a platform for considering this research question. To date, the CTN has not conducted research on medications for alcohol use disorders (AUDs), so greater adoption of innovative AUD pharmacotherapies by CTN-affiliated programs would suggest an added value of research network participation. Using longitudinal data from a pooled sample of CTN and non-CTN publicly funded treatment programs, we investigate adoption of tablet naltrexone and acamprosate over a 2-year period. CTN-affiliated programs were more likely to have adopted tablet naltrexone and acamprosate at 24-month follow-up, net of the effects of a range of organizational characteristics. Research network participation may thus enhance organizational innovativeness to include interventions beyond the scope of the network.

Original language	English
Pages (from-to)	275-283
Number of pages	9
Journal	Journal of Substance Abuse Treatment
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/j.jsat.2010.01.003
State	Published - Apr 2010

Bibliographical note

Funding Information:
The authors gratefully acknowledge the support from the NIDA (Grants R01DA13110 and R01DA14482 ) and from the National Institute on Alcohol Abuse and Alcoholism (Grants F32AA016872 and R01AA15974 ). The opinions expressed here are those of the authors and do not represent the official position of the National Institutes of Health.

Funding

The authors gratefully acknowledge the support from the NIDA (Grants R01DA13110 and R01DA14482 ) and from the National Institute on Alcohol Abuse and Alcoholism (Grants F32AA016872 and R01AA15974 ). The opinions expressed here are those of the authors and do not represent the official position of the National Institutes of Health.

Funders	Funder number
National Institute on Drug Abuse	R01DA013110, R01DA14482
National Institute on Alcohol Abuse and Alcoholism	F32AA016872, R01AA15974

Keywords

Acamprosate
Adoption of innovations
Clinical Trials Network
Research networks
Tablet naltrexone

ASJC Scopus subject areas

Psychiatric Mental Health
Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jsat.2010.01.003

Cite this

@article{98fb754c6c2c4f1c8c9c3678c5a5467a,

title = "The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation",

abstract = "Organizational participation in clinical research may lead to adoption of the intervention by treatment agencies, but it is not known whether research involvement enhances innovativeness beyond the specific interventions that are tested. The National Institute on Drug Abuse's Clinical Trials Network (CTN) is a platform for considering this research question. To date, the CTN has not conducted research on medications for alcohol use disorders (AUDs), so greater adoption of innovative AUD pharmacotherapies by CTN-affiliated programs would suggest an added value of research network participation. Using longitudinal data from a pooled sample of CTN and non-CTN publicly funded treatment programs, we investigate adoption of tablet naltrexone and acamprosate over a 2-year period. CTN-affiliated programs were more likely to have adopted tablet naltrexone and acamprosate at 24-month follow-up, net of the effects of a range of organizational characteristics. Research network participation may thus enhance organizational innovativeness to include interventions beyond the scope of the network.",

keywords = "Acamprosate, Adoption of innovations, Clinical Trials Network, Research networks, Tablet naltrexone",

author = "Abraham, {Amanda J.} and Knudsen, {Hannah K.} and Rothrauff, {Tanja C.} and Roman, {Paul M.}",

note = "Funding Information: The authors gratefully acknowledge the support from the NIDA (Grants R01DA13110 and R01DA14482 ) and from the National Institute on Alcohol Abuse and Alcoholism (Grants F32AA016872 and R01AA15974 ). The opinions expressed here are those of the authors and do not represent the official position of the National Institutes of Health.",

year = "2010",

month = apr,

doi = "10.1016/j.jsat.2010.01.003",

language = "English",

volume = "38",

pages = "275--283",

number = "3",

}

TY - JOUR

T1 - The adoption of alcohol pharmacotherapies in the Clinical Trials Network

T2 - The influence of research network participation

AU - Abraham, Amanda J.

AU - Knudsen, Hannah K.

AU - Rothrauff, Tanja C.

AU - Roman, Paul M.

N1 - Funding Information: The authors gratefully acknowledge the support from the NIDA (Grants R01DA13110 and R01DA14482 ) and from the National Institute on Alcohol Abuse and Alcoholism (Grants F32AA016872 and R01AA15974 ). The opinions expressed here are those of the authors and do not represent the official position of the National Institutes of Health.

PY - 2010/4

Y1 - 2010/4

N2 - Organizational participation in clinical research may lead to adoption of the intervention by treatment agencies, but it is not known whether research involvement enhances innovativeness beyond the specific interventions that are tested. The National Institute on Drug Abuse's Clinical Trials Network (CTN) is a platform for considering this research question. To date, the CTN has not conducted research on medications for alcohol use disorders (AUDs), so greater adoption of innovative AUD pharmacotherapies by CTN-affiliated programs would suggest an added value of research network participation. Using longitudinal data from a pooled sample of CTN and non-CTN publicly funded treatment programs, we investigate adoption of tablet naltrexone and acamprosate over a 2-year period. CTN-affiliated programs were more likely to have adopted tablet naltrexone and acamprosate at 24-month follow-up, net of the effects of a range of organizational characteristics. Research network participation may thus enhance organizational innovativeness to include interventions beyond the scope of the network.

AB - Organizational participation in clinical research may lead to adoption of the intervention by treatment agencies, but it is not known whether research involvement enhances innovativeness beyond the specific interventions that are tested. The National Institute on Drug Abuse's Clinical Trials Network (CTN) is a platform for considering this research question. To date, the CTN has not conducted research on medications for alcohol use disorders (AUDs), so greater adoption of innovative AUD pharmacotherapies by CTN-affiliated programs would suggest an added value of research network participation. Using longitudinal data from a pooled sample of CTN and non-CTN publicly funded treatment programs, we investigate adoption of tablet naltrexone and acamprosate over a 2-year period. CTN-affiliated programs were more likely to have adopted tablet naltrexone and acamprosate at 24-month follow-up, net of the effects of a range of organizational characteristics. Research network participation may thus enhance organizational innovativeness to include interventions beyond the scope of the network.

KW - Acamprosate

KW - Adoption of innovations

KW - Clinical Trials Network

KW - Research networks

KW - Tablet naltrexone

UR - http://www.scopus.com/inward/record.url?scp=77649189454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649189454&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2010.01.003

DO - 10.1016/j.jsat.2010.01.003

M3 - Article

C2 - 20117908

AN - SCOPUS:77649189454

SN - 0740-5472

VL - 38

SP - 275

EP - 283

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

IS - 3

ER -

The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this